Biodistribution and Elimination Study of Fluorine-18 Labeled Nε-Carboxymethyl-Lysine following Intragastric and Intravenous Administration

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Xu, Hongzeng ^a   Wang, Zhongqun ^a   Wang, Yan ^b   Hu, Shengda ^a   Liu, Naifeng ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b JIANGSU INSTITUTE OF NUCLEAR MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE N EPSILON CARBOXYMETHYL LYSINE F 18; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AMINO ACID URINE LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BIOLOGICAL ACTIVITY; CELL ASSAY; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG DETERMINATION; DRUG ELIMINATION; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DISTRIBUTION; STOMACH ABSORPTION; TISSUE DISTRIBUTION; URINARY EXCRETION;

ADMINISTRATION, INTRAVENOUS; ANIMALS; CELL LINE; FLUORINE RADIOISOTOPES; HEP G2 CELLS; HUMANS; LYSINE; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION;

EID: 84874684820     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057897     Document Type: Article

References (50)

1. Henle T, (2005) Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derivatives in foods. Amino Acids 29: 313-322.
2. Wang Z, Jiang Y, Liu N, Ren L, Zhu Y, et al. (2012) Advanced glycation end-product Nepsilon-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 221: 387-396.
3. Lin RY, Choudhury RP, Cai W, Lu M, Fallon JT, et al. (2003) Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 168: 213-220.
4. Semba RD, Fink JC, Sun K, Windham BG, Ferrucci L, (2010) Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging. J Ren Nutr 20: 74-81.
5. Perkins BA, Rabbani N, Weston A, Ficociello LH, Adaikalakoteswari A, et al. (2012) Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. PLoS One 7: e35655.
6. Zheng F, He C, Cai W, Hattori M, Steffes M, et al. (2002) Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 18: 224-237.
7. Tessier FJ, Birlouez-Aragon I, (2012) Health effects of dietary Maillard reaction products: the results of ICARE and other studies. Amino Acids 42: 1119-1131.
8. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, et al. (2005) Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 1043: 461-466.
9. Semba RD, Ang A, Talegawkar S, Crasto C, Dalal M, et al. (2012) Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study. Eur J Clin Nutr 66: 3-9.
10. Piroddi M, Palazzetti I, Quintaliani G, Pilolli F, Montaldi M, et al. (2011) Circulating levels and dietary intake of the advanced glycation end-product marker carboxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: a pilot study. J Ren Nutr 21: 329-339.
11. Ames JM, (2007) Evidence against dietary advanced glycation endproducts being a risk to human health. Mol Nutr Food Res 51: 1085-1090.
12. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, et al. (2007) Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 62: 427-433.
13. Serdons K, Verbruggen A, Bormans GM, (2009) Developing new molecular imaging probes for PET. Methods 48: 104-111.
14. Li Z, Conti PS, (2010) Radiopharmaceutical chemistry for positron emission tomography. Adv Drug Deliv Rev 62: 1031-1051.
15. Pawelke B, (2005) Metabolite analysis in positron emission tomography studies: examples from food sciences. Amino Acids 29: 377-388.
16. Lasne MC, Perrio C, Rouden J, Barre L, Roeda D, et al. (2002) Chemistry of beta(+)-emitting compounds based on fluorine-18. Top Curr Chem 222: 201-258.
17. Wuest F, (2005) Aspects of positron emission tomography radiochemistry as relevant for food chemistry. Amino Acids 29: 323-339.
18. Kuchar M, Pretze M, Kniess T, Steinbach J, Pietzsch J, et al. (2012) Site-selective radiolabeling of peptides by (18)F-fluorobenzoylation with [(18)F]SFB in solution and on solid phase: a comparative study. Amino Acids.
19. Vaidyanathan G, Zalutsky MR, (2006) Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F. Nat Protoc 1: 1655-1661.
20. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, et al. (1996) N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35: 8075-8083.
21. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW, (1995) N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878.
22. Ames JM, (2008) Determination ofNε-(Carboxymethyl)lysine in Foods and Related Systems. Annals of the New York Academy of Sciences 1126: 20-24.
23. Bergmann R, Helling R, Heichert C, Scheunemann M, Mading P, et al. (2001) Radio fluorination and positron emission tomography (PET) as a new approach to study the in vivo distribution and elimination of the advanced glycation endproducts N epsilon-carboxymethyllysine (CML) and N epsilon-carboxyethyllysine (CEL). Nahrung 45: 182-188.
24. Hultsch C, Hellwig M, Pawelke B, Bergmann R, Rode K, et al. (2006) Biodistribution and catabolism of 18F-labeled N-epsilon-fructoselysine as a model of Amadori products. Nucl Med Biol 33: 865-873.
25. Henle T, (2003) AGEs in foods: do they play a role in uremia? Kidney Int Suppl pp. S145-147.
26. Drusch S, Faist V, Erbersdobler HF, (1999) Determination of Nε-carboxymethyllysine in milk products by a modified reversed-phase HPLC method. Food Chemistry 65: 547-553.
27. Sano H, Nagai R, Matsumoto K, Horiuchi S, (1999) Receptors for proteins modified by advanced glycation endproducts (AGE)-their functional role in atherosclerosis. Mech Ageing Dev 107: 333-346.
28. Kuniyasu A, Ohgami N, Hayashi S, Miyazaki A, Horiuchi S, et al. (2003) CD36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3-L1 and human subcutaneous adipocytes. FEBS Lett 537: 85-90.
29. Ohgami N, Miyazaki A, Sakai M, Kuniyasu A, Nakayama H, et al. (2003) Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism. J Atheroscler Thromb 10: 1-6.
30. Ohgami N, Nagai R, Miyazaki A, Ikemoto M, Arai H, et al. (2001) Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 276: 13348-13355.
31. Svistounov D, Smedsrod B, (2004) Hepatic clearance of advanced glycation end products (AGEs)-myth or truth? J Hepatol 41: 1038-1040.
32. Smedsrød B, Melkko J, Araki N, Sano H, Horiuchi S, (1997) Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 322 (Pt 2) %W PubMed.cn pp. 567-573.
33. Horiuchi S, (2002) The liver is the main site for metabolism of circulating advanced glycation end products. J Hepatol 36: 123-125.
34. Gugliucci A, Bendayan M, (1996) Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39: 149-160.
35. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, et al. (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94: 6474-6479.
36. Forster A, Kuhne Y, Henle T, (2005) Studies on absorption and elimination of dietary maillard reaction products. Ann N Y Acad Sci 1043: 474-481.
37. Grunwald S, Krause R, Bruch M, Henle T, Brandsch M, (2006) Transepithelial flux of early and advanced glycation compounds across Caco-2 cell monolayers and their interaction with intestinal amino acid and peptide transport systems. Br J Nutr 95: 1221-1228.
38. Hull G, Woodside J, Ames J, Cuskelly G, (2012) Nå-(carboxymethyl)lysine content of foods commonly consumed in a Western style diet. Food Chemistry 131: 170-174.
39. Cai W, He JC, Zhu L, Chen X, Wallenstein S, et al. (2007) Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol 170: 1893-1902.
40. Henle T, (2007) Dietary advanced glycation end products-a risk to human health? A call for an interdisciplinary debate. Mol Nutr Food Res 51: 1075-1078.
41. Hellwig M, Geissler S, Matthes R, Peto A, Silow C, et al. (2011) Transport of free and peptide-bound glycated amino acids: synthesis, transepithelial flux at Caco-2 cell monolayers, and interaction with apical membrane transport proteins. Chembiochem 12: 1270-1279.
42. Hellwig M, Geissler S, Peto A, Knutter I, Brandsch M, et al. (2009) Transport of free and peptide-bound pyrraline at intestinal and renal epithelial cells. J Agric Food Chem 57: 6474-6480.
43. Ahmed KA, Muniandy S, Ismail IS, (2009) N(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status. J Clin Biochem Nutr 44: 14-27.
44. Park H, Adsit FG, Boyington JC, (2010) The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem 285: 40762-40770.
45. Fritz G, (2011) RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 36: 625-632.
46. Miyazaki A, Nakayama H, Horiuchi S, (2002) Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc Med 12: 258-262.
47. Rapin JR, Wiernsperger N, (2010) Possible links between intestinal permeability and food processing: A potential therapeutic niche for glutamine. Clinics (Sao Paulo) 65: 635-643.
48. Groschwitz KR, Hogan SP, (2009) Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 124: 3-20 quiz 21-22.
49. Ilchmann A, Burgdorf S, Scheurer S, Waibler Z, Nagai R, et al. (2010) Glycation of a food allergen by the Maillard reaction enhances its T-cell immunogenicity: role of macrophage scavenger receptor class A type I and II. J Allergy Clin Immunol 125: 175-183 e171-111.
50. Saito A, Takeda T, Sato K, Hama H, Tanuma A, et al. (2005) Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases. Ann N Y Acad Sci 1043: 637-643.